Riesgos Cardiovasculares de los Anticolinérgicos en EPOC

Revisión sistemática de los riesgos cardiovasculare en EPOC en el International Journal COPD

The relative risks for serious CV events, heart failure, and myocardial infarction were all significantly lower with tiotropium than placebo. It is not certain why such a wide disparity in findings exists among the published studies evaluating the CV risks of inhaled anticholinergic agents. Prospective, adequately powered RCTs are needed to provide more evidence for the CV safety of tiotropium.

* Seguridad cardiovascular del Tiotropio en paciente con EPOC. En Chest